Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
This trial has two separate groups (Cohort A and Cohort B). A person would need to meet the criteria for one of these groups.
Cohort A:
- Adults aged 18 or older
- Have a general health and activity level that falls within a certain range, as assessed by a doctor using a standard scale (confirm with trial site)
- Have been diagnosed with a specific type of lung cancer called extensive stage small cell lung cancer, confirmed by a tissue sample taken within the last 180 days
- Are planned to receive, or are currently receiving, a standard combination of chemotherapy and immunotherapy treatment
- Have received no more than 3 rounds (cycles) of that treatment at the time of joining the study
- Are considered suitable to receive radiation therapy to the chest area, as determined by the treating doctor
Cohort B:
- Adults aged 18 or older
- Have been diagnosed with a solid tumour cancer that has spread to the brain, with 1 to 5 affected areas identified by MRI scan within the last 60 days
- Each affected brain area included in the study must be between 2 and 5 cm in size, except for those located in the brainstem, which may be between 1.5 and 5 cm in size
Who may not be able to join:
Cohort A:
- People who have previously had radiation therapy to the chest area
Cohort B:
- People who have previously had radiation therapy to the whole brain
- People who have previously had surgery or targeted radiation treatment directed at any of the brain areas being considered for the study
- People whose cancer has spread to the lining surrounding the brain and spinal cord (a condition called leptomeningeal disease)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: NEIL DESAI, MD, MHS, University of Texas Southwestern Medical Center
Phone: 214 648 1836
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
COHORT A-assess safety of addition of PULSAR radiotherapy to thoracic tumor in ES-SCLC alongside chemoimmunotherapy, while making preliminary/exploratory assessments of disease response and dosimetric benefit to PULSAR; COHORT B-assesses ability to de-escalate dose in good responders by imaging using rule-based imaging-response guided omission of 2nd "pulse" of PULSAR fractionated SRS (fSRS) for brain metastases
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.